Dr. Karzai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 Center Drive
10/Room 12n226
Bethesda, MD 20892
Education & Training
- George Washington University School of Medicine and Health SciencesClass of 2005
Certifications & Licensure
- MD State Medical License 2009 - 2026
- DC State Medical License 2005 - 2009
- VA State Medical License 2005 - 2009
Clinical Trials
- Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer Start of enrollment: 2019 Dec 04
Roles: Contact, Principal Investigator
- Precision-Based Genomics in Prostate Cancer Start of enrollment: 2021 Sep 14
Roles: Principal Investigator, Contact
- Men at High Genetic Risk for Prostate Cancer Start of enrollment: 2019 Mar 27
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 126 citationsA PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening.Michael L. Beshiri, Caitlin M. Tice, Crystal Tran, Holly M. Nguyen, Adam G. Sowalsky
Clinical Cancer Research. 2018-09-01 - 28 citationsPhase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).Marijo Bilusic, Sheri McMahon, Ravi A. Madan, Fatima Karzai, Yo-Ting Tsai
Journal for Immunotherapy of Cancer. 2021-03-01 - 28 citationsApplications of large language models in cancer care: current evidence and future perspectives.Giovanni Maria Iannantuono, Dara Bracken-Clarke, Charalampos S Floudas, Mario Roselli, James L Gulley
Frontiers in Oncology. 2023-01-01
Journal Articles
- Tumor Cell Heterogeneity and Resistance; Report from the 2018 Coffey‐Holden Prostate Cancer Academy MeetingThomas A Hope, Kenneth J Pienta, Fatima Karzai, Simpa S Salami, Robert B Den, The Prostate
Press Mentions
- Olaparib Shows Synergy with Durvalumab in mCRPCFebruary 9th, 2018
- Olaparib, Durvalumab Combo Active in Prostate CancerFebruary 17th, 2017
- Enzalutamide Gets Added Approval for Prostate Cancer That Hasn’t SpreadJanuary 7th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: